NCT00039884Unknown2 期
Phase II Study of NESP (Novel Erythropoiesis Stimulating Protein) During Concurrent Chemo-Radiation for the Treatment of Cervical Carcinoma.
Mirhashemi, Ramin, M.D.2 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2001年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 64
- 试验地点
- 2
研究概览
简要总结
This is a clinical trial (a type of research study) designed to describe the efficacy (effectiveness) and toxicity (safety) of a new medical treatment, NESP (Novel Erythropoiesis Stimulating Protein). This study will be offered to patients with cervical cancer undergoing a combination of chemotherapy and radiation. This treatment may lower your red blood cells. The use of NESP may stimulate the body to produce more red blood cells. Our hypothesis is that higher red blood cells will be beneficial to the patient during treatment for cervical cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Consent form completed and signed
- •Hemoglobin between 9-13 g/dL
- •Life expectancy of at least 4 months
- •Karnofsky Performance Status =/> 70
- •No evidence of hemolysis, GI bleeding, or bleeding due to recent surgery
- •Adequate renal and liver function
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
2 期
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based TherapyMyelodysplastic SyndromesAcute Myeloid LeukemiaNCT05583552GCP-Service International West GmbH46
已完成
2 期
Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of CancerAnemiaNCT00095277Amgen220
招募中
2 期
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 BlockadeDigestive System CancersNCT06099821Peking University Cancer Hospital & Institute39
已完成
2 期
Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.Myelodysplastic SyndromesNCT01718379Groupe Francophone des Myelodysplasies132
招募中
2 期
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant TumorsOvarian CancerCervical CancerNCT06769152Shanghai Henlius Biotech190